Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
Charles River Laboratories International, Inc. reported that Chief Financial Officer Flavia H. Pease has informed the company she will resign as Corporate Executive Vice President and CFO, effective September 29, 2025. The company states that her decision is not due to any disagreements regarding financial statements, internal controls, operations, policies, or practices.
In connection with her departure, the Board has appointed Michael G. Knell, currently Corporate Senior Vice President and Chief Accounting Officer, to serve as interim Chief Financial Officer and principal financial officer, effective upon Ms. Pease’s departure and until a permanent successor is named. Mr. Knell has been with the company since 2017 and is a Certified Public Accountant with prior senior finance and audit experience. The company also issued a press release on September 16, 2025 announcing these changes.
Charles River Laboratories International, Inc. reported that Chief Financial Officer Flavia H. Pease has informed the company she will resign as Corporate Executive Vice President and CFO, effective September 29, 2025. The company states that her decision is not due to any disagreements regarding financial statements, internal controls, operations, policies, or practices.
In connection with her departure, the Board has appointed Michael G. Knell, currently Corporate Senior Vice President and Chief Accounting Officer, to serve as interim Chief Financial Officer and principal financial officer, effective upon Ms. Pease’s departure and until a permanent successor is named. Mr. Knell has been with the company since 2017 and is a Certified Public Accountant with prior senior finance and audit experience. The company also issued a press release on September 16, 2025 announcing these changes.
Charles River Laboratories (CRL) Form 144 shows a proposed sale of 400 shares of common stock to be executed through UBS Financial Services on 08/22/2025 with an indicated aggregate market value of $61,000. The securities were originally acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories, with 8,379 units reported as acquired and payment in cash on 05/13/2025. The filer also reported two recent sales in August 2025: 800 shares sold on 08/18/2025 for $126,054 and 400 shares sold on 08/08/2025 for $5,991. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Joseph W. LaPlume, an officer and director at Charles River Laboratories (CRL) serving as EVP, Corporate Strategy & Development, reported an open-market sale of 800 shares of CRL common stock on 08/18/2025 at a reported price of $157.60 per share. After the transaction he beneficially owned 24,116 shares. The Form 4 was signed on 08/20/2025. The filing discloses a single non-derivative sale and no derivatives or additional transactions.
Charles River Laboratories (CRL) Form 144 discloses a proposed sale of 22,500 shares of common stock through Merrill Lynch on or about 08/18/2025 with an aggregate market value of $3,420,000. The notice identifies the seller as Richard Wallman and shows prior acquisitions by the seller including RSU vesting from 2017–2019 and multiple open-market purchases in June–July 2025 totaling 15,000 shares. The filing also reports recent sales by the same person in the past three months: 4,000 shares on 06/23/2025 for $550,000 and 8,500 shares on 07/21/2025 for $1,275,000. The filer certifies no undisclosed material adverse information.
Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600. The shares represent part of outstanding common stock of 49,120,000 and an approximate sale date of 08/18/2025 on the NYSE. The filing shows the shares were acquired as Performance Stock Units on 01/27/2023 from Charles River Laboratories and that payment at sale is expected in cash. The filer previously sold 400 shares on 08/07/2025 for $59,991. The notice includes the customary attestation that the seller is unaware of undisclosed material adverse information.
Nomura Holdings, Inc. reports beneficial ownership of 2,681,669 shares of Charles River Laboratories common stock, representing 5.4% of the outstanding class. The total includes 473,087 shares held by Nomura Global Financial Products, Inc. (NGFP), 1,096,182 shares held by Nomura Securities International, Inc. (NSI), and call options exercisable within 60 days covering 1,112,400 shares (1,100,000 by NGFP and 12,400 by NSI). The percent is calculated using 49,209,000 shares outstanding as of June 28, 2025, per the issuer's quarterly report. The filing states these holdings were acquired and are held in the ordinary course of business.
Charles River Laboratories EVP Joseph W. LaPlume reported a sale of 400 shares of common stock on 08/07/2025 at $150.04 per share. After the transaction he directly owned 24,916 shares. The filing is a routine Form 4 disclosure recording an officer's change in beneficial ownership and shows no derivative transactions.